Neurological conditions affect over 700 million people globally and almost everyone – from people, their families, caregivers and communities – has been impacted by one.
And we have seen how people’s identities – the little things that make them who they are – can dim in the face of such conditions.
Conditions of the nervous system have historically been the most complex to understand and treat. Alzheimer's disease has been called the epidemic of our generation; Huntington’s disease, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease communities are anxiously awaiting disease-modifying treatments. Fortunately, there has been scientific progress for some neurological disorders – such as multiple sclerosis (MS) and spinal muscular atrophy (SMA) – that have successfully slowed the progression of the disease.
Roche in Neuroscience and Rare Disease
Our company was founded over 120 years ago on the idea that the rigorous pursuit of ground-breaking science could transform the lives of people facing serious and life-threatening diseases. By following this path, we have been responsible for major therapeutic advances in some of the world’s most prevalent disease areas – oncology, rheumatology and ophthalmology.
For the first time in history, we have the tools, technology and scientific insights that we believe will lead to new types of medicines that can alter or even reverse the trajectory of neurological diseases.
Roche’s aspiration in neuroscience and rare disease is to preserve the innate brilliance inside us all, what makes us unique as individuals - beyond any disease or condition.